- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02242032
Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease
A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single-center, dose escalation, randomized, double-masked, placebo-controlled, Phase 1/2a trial designed to evaluate the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye for up to 4-weeks of treatment and up to 8 scheduled in clinic visits. This study will conduct a consecutive dose escalation of the following concentrations of P-321 Ophthalmic Solution given two times a day via ocular instillation: 0.0005% (Cohort 1), 0.0015% (Cohort 2), 0.005% (Cohort 3), and 0.01% (Cohort 4). Up to 48 subjects will be enrolled in four consecutive cohorts. Subjects will be randomized to P-321 Ophthalmic Solution or placebo in a 3:1 ratio.
Safety and tolerability assessments, drug plasma concentrations and drug urine concentrations will be evaluated throughout the study in all cohorts.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Artesia, California, United States, 90701
- Sall Research Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Individuals of both genders and any race will be eligible for study participation if they:
- Provide written informed consent.
- Are 18 - 80 years of age.
- Corneal fluorescein staining score ≥2/15 on the NEI/Industry scale
- Conjunctival lissamine staining score of ≥ 2/18 on the NEI/Industry scale
- Schirmer <10mm/5min
- Are willing and able to follow instructions and can be present for the required study visits for the duration of the study.
- Female patients of child bearing potential must have a negative urine pregnancy test at Screening and agree to use a medically acceptable form of birth control. Male subjects who are sexually active must be willing to use highly effective contraception (i.e., less than 1% failure rate) during heterosexual intercourse from Day 1 through completion of the study.
- Have a history of Dry Eye Disease in both eyes supported by a previous clinical diagnosis or have a self-reported history of subjective complaints for at least 4 months prior to Screening, low tear volume, and ocular staining.
- Have documented history of topical lubricants at least daily or the desire to use topical lubricants in the past 4 months.
- Have normal lid anatomy
Exclusion Criteria:
Individuals are not eligible for study participation if:
- Have anterior segment eye disease except primary dry eye.
- Patients with an identifiable or suspected secondary dry eye, i.e., a documented or likely systemic, ocular, pharmacologic, post-traumatic, post-surgical, or external cause for dry eye symptoms or ocular surface staining.
- Patients with current punctal plugs, punctal occlusion, or history of nasolacrimal duct obstruction are excluded.
- Have a history of glaucoma or intraocular pressure (IOP) > 25 mmHg at the Screening Visit (Visit 1) or a history of elevated IOP within the past year prior to Visit 1
- Contact lenses wear in the previous 30 days or during the Treatment Phase of the study.
- Use of lid scrubs (including baby shampoos)
- Known hypersensitivity to the study investigational medicinal product, or formulation excipients, including amiloride or related drugs or allergies to the components of the study drug.
- Any significant chronic illness that, in the opinion of the Principal Investigator (PI), could interfere with the study parameters.
- Use of any investigational product or device within 30 days prior to the Screening Visit or during the study.
- Those unable in the opinion of the PI to comply fully with the study requirements or complete the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: P-321
P-321 Ophthalmic Solution
|
Other Names:
|
Placebo Comparator: P-321 Ophthalmic Solution Placebo
|
Placebo to match P-321 Ophthalmic Solution
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with adverse events
Time Frame: Days 0, 1, 2, 8, 15, 22 and 28
|
One primary objective of this trial is to assess the safety of P-321 Ophthalmic Solution versus placebo in subjects with moderate dry eye disease at 14 days (Cohorts 1-4) and 28 days (Cohort 4 only).
|
Days 0, 1, 2, 8, 15, 22 and 28
|
Changes from baseline in 14 days in visual acuity.
Time Frame: Change from baseline at 14 days.
|
Change from baseline at 14 days in visual acuity.
|
Change from baseline at 14 days.
|
Change from baseline at 28 days in visual acuity for Cohort 4 only.
Time Frame: Change from baseline at 28 days in visual acuity.
|
Change from baseline at 28 days in visual acuity for Cohort 4 only.
|
Change from baseline at 28 days in visual acuity.
|
Changes from baseline at 14 days in corneal staining.
Time Frame: Changes from baseline at 14 days.
|
Changes from baseline at 14 days in corneal staining.
|
Changes from baseline at 14 days.
|
Changes from baseline at 28 days in corneal staining for cohort 4 only.
Time Frame: Changes from baseline at 28 days.
|
Changes from baseline at 28 days in corneal staining for cohort 4 only.
|
Changes from baseline at 28 days.
|
Changes from baseline at 14 days in conjunctival staining.
Time Frame: Changes from baseline at 14 days
|
Changes from baseline at 14 days in conjunctival staining.
|
Changes from baseline at 14 days
|
Changes from baseline at 28 days in conjunctival staining for Cohort 4 only.
Time Frame: Changes from baseline at 28 days
|
Changes from baseline at 28 days in conjunctival staining for Cohort 4 only.
|
Changes from baseline at 28 days
|
Changes from baseline at 14 days in intraocular pressure.
Time Frame: Changes from baseline at 14 days.
|
Changes from baseline at 14 days in intraocular pressure.
|
Changes from baseline at 14 days.
|
Changes from baseline at 28 days in intraocular pressure. for Cohort 4 only.
Time Frame: Changes from baseline at 28 days
|
Changes from baseline at 28 days in intraocular pressure.
for Cohort 4 only.
|
Changes from baseline at 28 days
|
Changes from baseline at 14 days in ophthalmoscopy.
Time Frame: Changes from baseline at 14 days
|
Changes from baseline at 14 days in ophthalmoscopy.
|
Changes from baseline at 14 days
|
Changes from baseline at 28 days in ophthalmoscopy for Cohort 4 only.
Time Frame: Changes from baseline at 28 days
|
Changes from baseline at 28 days in ophthalmoscopy for Cohort 4 only.
|
Changes from baseline at 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure plasma P-321 concentrations
Time Frame: Pre-dose 0.5, 1, 2, 4, and 6 hours post dosing on Days 1 and Day 15 and pre-dose on Day 8.
|
Drug plasma concentrations will be evaluated pre-dose 0.5, 1, 2, 4, and 6 hours post dosing on Days 1 and 15 and pre-dose on Day 8.
|
Pre-dose 0.5, 1, 2, 4, and 6 hours post dosing on Days 1 and Day 15 and pre-dose on Day 8.
|
Measure urine concentrations of P-321
Time Frame: At multiple timepoints throughout the study
|
Drug urine concentrations will be evaluated at Day 1 and Day 15.
|
At multiple timepoints throughout the study
|
Measure tear concentrations of P-321
Time Frame: pre-dose 0.5, 1, 2, 4, and 6 hours post dosing on Day 1 and Day 15 and pre-dose on Day 8.
|
Drug tear concentrations will be evaluated at all visits post dose.
|
pre-dose 0.5, 1, 2, 4, and 6 hours post dosing on Day 1 and Day 15 and pre-dose on Day 8.
|
Measure plasma P-321 concentrations in Cohort 4
Time Frame: pre-dose on Day 8 and Day 22, and pre-dose, 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose on Day 28
|
Measure plasma P-321 concentrations in Cohort 4
|
pre-dose on Day 8 and Day 22, and pre-dose, 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose on Day 28
|
Measure urine concentrations of P-321 in Cohort 4
Time Frame: Day 28
|
Measure urine concentrations of P-321 in Cohort 4
|
Day 28
|
Measure tear concentrations of P-321 in Cohort 4
Time Frame: pre-dose on Day 8 and Day 22, and pre-dose, 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose on Day 28
|
Measure tear concentrations of P-321 in Cohort 4
|
pre-dose on Day 8 and Day 22, and pre-dose, 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose on Day 28
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kenneth Sall, MD, Sall Research Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-321-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Disease
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Laboratorios Sophia S.A de C.V.Not yet recruitingOcular Surface Disease | Dry Eye Disease | Dry Eye Sensation
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
LantibioRiver Plate Biotechnology, Inc.; Rx Development Resources, LLCCompletedSafety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye SyndromeDry Eye DiseaseUnited States
-
Fundación Oftalmológica Los AndesAlcon ResearchNot yet recruitingCataract | Dry Eye Syndrome | Dry Eye Disease | Phacoemulsification | Evaporative Dry Eye
-
Vienna Institute for Research in Ocular SurgeryTerminated
-
Novaliq GmbHCompletedDry Eye Disease (DED)United States
-
Novaliq GmbHCompletedDry Eye Disease (DED)United States
Clinical Trials on P-321 Ophthalmic Solution placebo
-
Parion SciencesTerminatedDry Eye DiseaseUnited States
-
Parion SciencesTerminatedDry Eye DiseaseUnited States
-
Kowa Research Institute, Inc.CompletedFuchs' Endothelial Corneal DystrophyUnited States, Australia, Germany, Spain, Denmark
-
Mimetogen Pharmaceuticals USA, Inc.CompletedDry Eye SyndromesUnited States
-
Laboratorios Sophia S.A de C.V.WithdrawnConjunctivitis, Allergic | Seasonal Allergic Conjunctivitis | Ocular Itching | Ocular Allergy | Perennial Allergic ConjunctivitisMexico
-
Rigel PharmaceuticalsCompletedChronic Graft-versus-host DiseaseUnited States
-
Santen Pharmaceutical Co., Ltd.CompletedPrimary Open Angle Glaucoma | Ocular HypertensionJapan
-
Herantis Pharma Plc.ORA, Inc.CompletedDry Eye SyndromeUnited States
-
ORA, Inc.Palatin Technologies, IncCompletedDry Eye DiseaseUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaJapan